Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06886269 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06886269 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 8 participants.
The verdict
NCT06886269, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.
Interventions
- DRUG 14C-VX-993
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2025-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06886269
The ClinicalTrials.gov registry entry for NCT06886269 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 14C-VX-993 is the first listed.
NCT06886269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06886269 about?
NCT06886269 is a clinical study titled "A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose". The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.
What is the current status of trial NCT06886269?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-03-21. Estimated completion is 2025-05-17.
What interventions are being tested in trial NCT06886269?
The interventions under investigation include: 14C-VX-993 (DRUG).
Who is sponsoring clinical trial NCT06886269?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.